Step 1 topics → Reproductive → Complete Androgen Insensitivity Syndrome (CAIS)

Complete Androgen Insensitivity Syndrome (CAIS)

USMLE Step 1 trap: Incorrectly predicts Müllerian structures in CAIS because the patient looks female, forgetting MIS acts via a separate receptor. CAIS patients lack Müllerian structures (uterus, tubes, upper vagina) because their testes produce functional MIS, which acts independently of the androgen receptor.

Complete Androgen Insensitivity Syndrome (CAIS) is one of the most reliably tested disorders of sex development on USMLE Step 1 — and the trap students fall into is assuming a female-appearing phenotype means female internal organs. CAIS is a 46,XY condition caused by a loss-of-function mutation in the androgen receptor (AR). The testes develop normally (SRY is intact), produce testosterone and MIS, but end-organ tissues cannot respond to androgens. The result is a phenotypically female individual with no uterus, no fallopian tubes, a blind-ending vagina, and testes in the inguinal canal or labia. The exam loves this condition because it exposes whether you actually understand the logic of sexual differentiation — not just the phenotype, but the mechanism behind each finding.

The exam tests CAIS from multiple angles: pure recall of the phenotype, mechanistic reasoning (why do breasts form? why no Müllerian structures?), clinical management questions about gonadectomy timing, and high-yield differentials against 5α-reductase deficiency. Passage-based questions will give you lab values — elevated testosterone, normal/high LH, absent DHT or abnormal testosterone:DHT ratio — and ask you to distinguish or explain. The trap is surface-level pattern matching: 'looks female → must have female organs' is exactly the reasoning the exam is designed to punish.

The trickiest part of CAIS is that several independent hormonal pathways operate simultaneously, and students collapse them into one. Müllerian regression, androgen-driven masculinization, and estrogen-driven feminization all have separate receptors. The androgen receptor defect knocks out only one of these. USMLE Step 1 exploits that confusion hard — especially around why breasts develop (hint: it's not ovaries) and why the uterus is absent (hint: it's not because androgens build it).

From real student decks
46%have cards covering this topic
22%have mature cards

Common misconceptions

Common mistake
Wrong: CAIS patients have a uterus and fallopian tubes because they appear phenotypically female.
Right: CAIS patients lack Müllerian structures (uterus, tubes, upper vagina) because their testes produce functional MIS, which acts independently of the androgen receptor.
MIS (Müllerian Inhibiting Substance, also called AMH) is produced by Sertoli cells and acts through its own receptor — the AMHR2 — completely independent of the androgen receptor. In CAIS, the testes are functional and secrete MIS normally, so Müllerian structures (uterus, fallopian tubes, upper vagina) are fully regressed. The female-appearing external phenotype has nothing to do with Müllerian persistence; those structures were eliminated by MIS before the androgen insensitivity even mattered.
Common mistake
Wrong: Breast development in CAIS is driven by estrogen produced by the ovaries.
Right: CAIS patients have testes (no ovaries); breast development results from peripheral aromatization of testicular testosterone to estrogen, which acts on estrogen receptors that are unaffected by the androgen receptor defect.
CAIS patients have no ovaries — they have testes. Breast development is not ovarian in origin. Testicular testosterone is produced in normal or elevated amounts, but because peripheral aromatase converts testosterone to estradiol, circulating estrogen rises. Estrogen receptors are completely intact in CAIS (only the androgen receptor is defective), so estrogen acts normally on breast tissue and drives feminizing puberty including breast development.
Common mistake
Wrong: Gonadectomy in CAIS should be performed immediately at diagnosis in childhood to prevent malignancy.
Right: Gonadectomy in CAIS is typically deferred until after puberty so that endogenous testosterone can aromatize to estrogen and drive feminizing puberty; malignancy risk before puberty is low (~3%).
The malignancy risk from retained gonads in CAIS is real but low before puberty — estimated around 2-3%. The benefit of keeping the testes through puberty is that endogenous testosterone undergoes peripheral aromatization to estrogen, which drives a natural, endogenous feminizing puberty without requiring exogenous hormone replacement. Removing the testes immediately in childhood eliminates that benefit and necessitates early hormone replacement. Current consensus is to defer gonadectomy until after puberty, then remove the gonads to eliminate long-term malignancy risk.
Common mistake
Wrong: CAIS and 5α-reductase deficiency are indistinguishable because both present with 46,XY and feminized external genitalia.
Right: Key distinctions: CAIS has no virilization at puberty and absent pubic/axillary hair, while 5α-reductase deficiency virilizes at puberty; CAIS has high testosterone with normal DHT, while 5α-reductase deficiency has high testosterone:DHT ratio.
Both CAIS and 5α-reductase deficiency present in 46,XY individuals with feminized external genitalia at birth, which is why students conflate them. The key divergence happens at puberty: in CAIS, there is no virilization because the AR is non-functional, and pubic/axillary hair (which requires AR signaling) is sparse or absent; in 5α-reductase deficiency, the AR is intact and testosterone can still activate it directly, so puberty brings significant virilization (clitoromegaly, voice deepening, muscle mass). On labs, 5α-reductase deficiency shows a high testosterone:DHT ratio (DHT cannot be made), while CAIS shows elevated testosterone with normal DHT but elevated LH due to lost androgen feedback.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Know the complete internal and external phenotype of CAIS: phenotypically female external genitalia, absent uterus and fallopian tubes, blind-ending vagina, testes present (often inguinal), and sparse or absent pubic and axillary hair.
  2. Understand the mechanism behind each finding: the AR defect prevents virilization and hair growth, but MIS (acting via its own receptor) still regresses Müllerian structures, and peripheral aromatization of testicular testosterone still drives breast development via estrogen receptors.
  3. Know the rationale for deferring gonadectomy until after puberty in CAIS: endogenous testosterone aromatizes to estrogen and drives natural feminizing puberty, and malignancy risk before puberty is low enough that immediate removal is not warranted.
  4. Distinguish CAIS from 5α-reductase deficiency: CAIS patients do not virilize at puberty and lack pubic/axillary hair, while 5α-reductase deficiency patients virilize at puberty; lab findings differ with a high testosterone:DHT ratio in 5α-reductase deficiency but not in CAIS.

Can you avoid these mistakes?

A 16-year-old phenotypically female patient presents with primary amenorrhea. Exam reveals breast development, sparse pubic hair, and a blind-ending vagina. Imaging shows no uterus. Karyotype is 46,XY. What is the most likely diagnosis, and why does this patient have breast development despite having no ovaries?
In CAIS, why are Müllerian structures (uterus, fallopian tubes) absent, even though the patient appears phenotypically female and has no functional androgen signaling?
A physician recommends immediate gonadectomy in a 6-year-old with newly diagnosed CAIS. A colleague disagrees and suggests waiting until after puberty. What is the strongest argument for deferring surgery, and what risk must be weighed against it?
A 46,XY patient raised female undergoes workup for primary amenorrhea. Lab results show testosterone in the normal male range, DHT also in the normal range, and elevated LH. A second 46,XY patient has similarly elevated testosterone but a markedly low DHT with virilization at puberty. What diagnosis does each lab pattern suggest, and what single clinical feature most reliably distinguishes them?

Related topics

Gonadal Differentiation (SRY, MIS, Testosterone) Müllerian vs Wolffian Duct Derivatives 5α-Reductase Deficiency Müllerian Anomalies (Bicornuate, Septate, MRKH)

See how your Anki deck covers this topic.

Upload your deck for a free audit →